Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies

Next Previous
Trial Profile

A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Neflamapimod (Primary)
  • Indications Lewy body disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms RewinD-LB
  • Sponsors CervoMed; EIP Pharma

Most Recent Events

  • 02 Apr 2025 According to a CervoMed media release, the company expects to complete the full 32-weeks of the Extension phase of the RewinD-LB study and engage with regulatory authorities to discuss finalizing Phase 3 plans for neflamapimod after these additional data become available later in 2H 2025.
  • 02 Apr 2025 According to a CervoMed media release, company announced that investigators plan to present results, including new results, from the Extension phase of the Phase 2b RewinD-LB study that show neflamapimod demonstrated a clinically meaningful effect on slowing clinical progression in patients with DLB in an oral presentation during the 19th International Conference on Alzheimers and Parkinsons Disease and Related Neurologic Disorders (AP/PD™) on Saturday, April 5, 2025.
  • 02 Apr 2025 Results presented in the CervoMed media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top